Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland

Pediatric Pulmonology

Volumn 51, Issue 4, 2016, Pages 379-385

  Groves, H E ^a   Jenkins, L ^a   Macfarlane, M ^a   Reid, A ^a   Lynn, F ^b   Shields, M D ^b  

^a ROYAL BELFAST HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

bronchiolitis; children; cystic fibrosis; palivizumab; respiratory syncytial virus

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT;

ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; CHILD; CHILD GROWTH; CHILD HOSPITALIZATION; CYSTIC FIBROSIS; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; INFECTION PREVENTION; IRELAND; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; COMPLICATION; COST BENEFIT ANALYSIS; EPIDEMIOLOGY; HOSPITALIZATION; INFANT; ISOLATION AND PURIFICATION; NORTHERN IRELAND; PATHOPHYSIOLOGY; PSEUDOMONAS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; CYSTIC FIBROSIS; FEMALE; HOSPITALIZATION; HUMANS; INFANT; MALE; NORTHERN IRELAND; PALIVIZUMAB; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84961401635     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23376     Document Type: Article

References (31)

1. Goddard NL, Cooke MC, Gupta RK, Nguyen-Van-Tam JS,. Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom. Epidemiol Infect 2007; 135: 159-162.
2. Muller-Pebody B, Edmunds WJ, Zambon MC, Gay NJ, Crowcroft NS,. Contribution of RSV to bronchiolitis and pneumonia-associated hospitalizations in English children, April 1995-March 1998. Epidemiol Infect 2002; 129: 99-106.
3. Purcell K, Fergie J,. Driscoll Children's Hospital respiratory syncytial virus database: risk factors, treatment, and hospital course in 3,308 infants and young children, 1991-2002. Pediatr Infect Dis J 2004; 23: 418-423.
4. Greenough A, Alexander J, Burgess S, Bytham J, Chetcuti PAJ, Hagan J, Lenney W, Melville S, Shaw NJ, Boorman J, et al., Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child 2004; 89: 673-678.
5. Mussi-Pinhata M, Motta F, Freimanis-Hance L, Freimanis-Hance L, de Souza R, Szyld E, Succi RCM, Christie CDC, Rolon MJ, Ceriotto M, et al., Lower respiratory tract infections among human immunodeficiency virus-exposed, uninfected infants. IntJ Infect Dis 2010; 14: e176-e182.
6. Thornburn K,. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus (RSV) infection. Arch Dis Child 2009; 94: 99-103.
7. Collinson J, Nicholson KG, Cancio E, Ashman J, Ireland DC, Hammersley V, Kent J, O'Callaghan C,. Effects of upper respiratory tract infections in patients with cystic fibrosis. Thorax 1996; 51: 1115-1122.
8. Peterson NT, Hoiby N, Mordhorst CH, Lind K, Flensborg EW, Bruun B,. Respiratory infections in cystic fibrosis patients caused by virus, Chlamydia and mycoplasma-possible synergism with Pseudomonas aeruginosa. Acta Pediatr Scand 1981; 70: 623-628.
9. Zheng S, De BP, Choudhary S, Comhair SA, Goggans T, Slee R, Williams BRG, Pilewski J, Haque SJ, Erzurum SC,. Impaired innate host defense causes susceptibility to respiratory virus infections in cystic fibrosis. Immunity 2003; 137: 35-40.
10. Raza MW, El Ahmer OR, Ogilvie MM, Blackwell CC, Saadi AT, Elton RA, Weir DM,. Infection with respiratory syncytial virus enhances expression of native receptors for non-pilate Neisseria meningitides on Hep-2 cells. FEMS Immunol Med Microbiol 1999; 23: 115-1124.
11. Speer ME, Fernander CJ, Boron M, Groothuis JR,. Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis. Pediatr Infect Dis J 2008; 27: 559-561.
12. Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S,. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr Pulmonol 2008; 43: 169-174.
13. Robinson KA, Odelola OA, Saldanha IJ, Mckoy NA,. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis (Review). Cochrane Database Syst Rev 2013; DOI: 10.1002/14651858
14. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Jr, Connor EM, Sondheimer HM,. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus disease in young children with haemodynamically significant congenital heart disease. J Pediatr 2003; 143: 532-540.
15. McCormick J, Southern KW,. A survey of palivizumab for infants with cystic fibrosis in the UK. Arch Dis Child 2007; 92: 87-88.
16. Giusti R,. North American synagis prophylaxis survey. Pediatr Pulmonol 2009; 44: 96-98.
17. Cohen AH, Boron ML, Dingivan C,. A phase IV study of the safety of SynagisTm (Palivizumab) for prophylaxis of respiratory syncytial virus. Proc Am Thorac Soc. 2005; 2: A189.
18. Winterstein AG, Eworuke E, Xu D, Schuler P,. Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis. Pediatr Pulmonol 2013; 48: 874-884.
19. Sanchez-Solis M, Gartner S, Bosch-Gimenez V, Garcia-Marcos L,. Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis. Allergol Immunopathol 2015; 43: 298-303.
20. Department of Health. NHS Reference Costs 2013-2014. London: Department of Health; 2014.
21. British National Formulary. London: BMJ Group and the Royal Pharmaceutical Society of Great Britain; 2014.
22. Curtis L,. Unit Costs of Health and Social Care 2014. Canterbury: Personal Social Services Research Unit, University of Kent; 2014.
23. Linnane B, Kiernan MG, Kearse NH, Dunne L, Dunne CP,. Anti-RSV prophylaxis efficacy for infants and young children with cystic fibrosis in Ireland. Multidis Resp Med 2015; 10: 32.
24. Davies JC, Cunningham S, Alton EWFW, Innes JA,. Lung clearance index in CF: a sensitive marker of lung disease severity. Thorax 2008; 63: 96-97.
25. Welsh L, Robertson CF, Ranganathan SC,. Increased rate of lung function decline in Australian adolescents with cystic fibrosis. Pediatr Pulmonol 2014; 49: 873-877.
26. Bonfield TL, Konstan MW, Berger M,. Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol 1999; 104: 72-78.
27. Armstrong D, Grimwood K, Carlin JB, Carzino R, Hull J, Olinsky A, Phelan PD,. Severe respiratory infections in infants with cystc fibrosis. Pediatr Pulmonol 1998; 26: 371-379.
28. Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ,. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 1988; 113: 826-830.
29. Rosenfeld M, Emerson J, McNamara S, Thompson V, Ramsey BW, Morgan W, Gibson RL,. Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort. J Cystic Fib 2012; 11: 446-453.
30. Thomas M, Bedford-Russell A, Sharland M,. Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin. Arch Dis Child 2000; 83: 122-127.
31. Marchetti A, Lau H, Magar R, Wang L, Devercelli G,. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings. Clin Ther 1999; 21: 752-766.